Eli Lilly to Acquire AtaiBeckley in Up to $3.8 Billion Psychedelic Depression Deal
Eli Lilly is acquiring clinical-stage psychedelic biotech AtaiBeckley in a deal worth up to $3.8 billion, expanding its neuroscience portfolio with experimental therapies for treatment-resistant depression and marking a major investment in psychedelic medicine.

